Thermo Fisher sales increase 9% to $12.14 billion in Q3

• Thermo Fisher Scientific (NYSE:TMO) reported third-quarter 2026 revenue of $12.14 billion, up 9% year over year, including 6% organic revenue growth.
• GAAP diluted earnings per share increased 9% to $4.64, while non-GAAP adjusted EPS rose 15% to $6.68.
• Management attributed the results to its growth strategy, customer demand and the PPI Business System, which supports operational improvements across the company.

Thermo Fisher Scientific (NYSE:TMO) reported third-quarter 2026 revenue of $12.14 billion, up 9% year over year, supported by growth across its scientific products and services businesses.

Organic revenue increased 6%, indicating underlying business growth after excluding specified acquisition, divestiture and foreign currency effects from reported revenue.

GAAP diluted earnings per share increased 9% to $4.64, compared with approximately $4.27 in the corresponding quarter of 2025.

Adjusted diluted earnings per share rose 15% to $6.68, compared with $5.79 a year earlier, reflecting stronger profitability on a non-GAAP basis.

Thermo Fisher attributed its performance to continued execution of its growth strategy and the PPI Business System, which management uses to support productivity and operational efficiency.

The company serves pharmaceutical, biotechnology, healthcare and academic research customers, providing scientific instruments, laboratory products, diagnostics and services supporting drug development and manufacturing.